| | | | | 1 | | | |
| | | | | 5 | | | |
| | | | | 10 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 21 | | | |
| | | | | 23 | | | |
| | | | | 25 | | | |
| | | | | 38 | | | |
| | | | | 39 | | | |
| | | | | 40 | | | |
| | | | | 43 | | | |
| | | | | 44 | | | |
| | | | | 45 | | | |
| | | | | 46 | | | |
| | | | | 48 | | | |
| | | | | 55 | | | |
| | | | | 56 | | |
| | |
As of April 28, 2023
|
| |||||||||||||||
Total Number of Directors
|
| |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did Not
Disclose Gender |
| ||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | |
Directors
|
| | | | 1 | | | | | | 5 | | | | | | | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | |
African American or Black
|
| | | | | | | | | | | | | | | | | | |
Alaskan Native or Native American
|
| | | | | | | | | | | | | | | | | | |
Asian
|
| | | | | | | | | | | | | | | | | | |
Hispanic or Latinx
|
| | | | | | | | | | | | | | | | | | |
Native Hawaiian or Pacific Islander
|
| | | | | | | | | | | | | | | | | | |
White
|
| | | | 1 | | | | | | 5 | | | | | | | | |
Two or More Races or Ethnicities
|
| | | | | | | | | | | | | | | | | | |
LGBTQ+
|
| | | | | | | | | | | | | | | | | | |
Did Not Disclose Demographic Background
|
| | | | | | | | | | | | | | | | | | |
Director Nominee
|
| |
Since
|
| |
Principal Occupation or Experience
|
| |
Committees
|
|
Gregory J. Divis | | |
2019
|
| | Chief Executive Officer of the Company | | | | |
Dr. Eric J. Ende | | |
2018
|
| | President at Ende BioMedical Consulting Group | | |
(2)(4*)
|
|
Geoffrey M. Glass | | |
2018
|
| | President and Chief Executive Officer of Kiniciti, LLC | | |
(1)(2)(4)
|
|
Dr. Mark A. McCamish | | |
2019
|
| | President and Chief Executive Officer of IconOVir Bio, Inc. | | |
(2)(3)
|
|
Linda S. Palczuk | | |
2018
|
| | Chief Executive/Operating Officer of Life Sciences Companies | | |
(3*)(4)
|
|
Peter J. Thornton | | |
2017
|
| | President and Chief Financial Officer of Envetec Sustainable Technologies Limited | | |
(2*)(3)
|
|
Name
|
| |
Age
|
| |
Position
|
|
Gregory J. Divis | | |
56
|
| | Chief Executive Officer and Director | |
Thomas S. McHugh | | |
58
|
| | Chief Financial Officer | |
Richard J. Kim | | |
53
|
| | Chief Commercial Officer | |
Geoffrey M. Glass | | |
49
|
| | Chair of the Board of Directors | |
Eric J. Ende, M.D. | | |
54
|
| | Director | |
Mark A. McCamish, M.D., Ph.D. | | |
71
|
| | Director | |
Linda S. Palczuk | | |
61
|
| | Director | |
Peter J. Thornton | | |
58
|
| | Director | |
| | |
Annual Retainer
prior to 2022 Annual Meeting |
| |
Annual Retainer
following 2022 Annual Meeting |
| ||||||
Board of Directors: | | | | | | | | | | | | | |
All non-employee members
|
| | | $ | 52,100 | | | | | $ | 52,100 | | |
Additional retainer for Non-Executive Chair of the Board
|
| | | $ | 30,000 | | | | | $ | 35,000 | | |
Audit Committee: | | | | | | | | | | | | | |
Chair
|
| | | $ | 20,000 | | | | | $ | 20,000 | | |
Non-Chair members
|
| | | $ | 10,000 | | | | | $ | 10,000 | | |
Compensation Committee: | | | | | | | | | | | | | |
Chair
|
| | | $ | 15,000 | | | | | $ | 15,000 | | |
Non-Chair members
|
| | | $ | 7,500 | | | | | $ | 7,500 | | |
Nominating and Corporate Governance Committee: | | | | | | | | | | | | | |
Chair
|
| | | $ | 10,000 | | | | | $ | 10,000 | | |
Non-Chair members
|
| | | $ | 5,000 | | | | | $ | 5,000 | | |
Name
|
| |
Fees Earned or
Paid in Cash ($)(1) |
| |
Option
Awards $(2)(3) |
| |
Stock
Awards ($) |
| |
Total
Compensation ($) |
| ||||||||||||
Geoffrey M. Glass(4)
|
| | | | 99,183 | | | | | | 157,932 | | | | | | — | | | | | | 257,116 | | |
Dr. Eric J. Ende(5)
|
| | | | 72,100 | | | | | | 157,932 | | | | | | — | | | | | | 230,032 | | |
Dr. Mark A. McCamish(6)
|
| | | | 69,600 | | | | | | 157,932 | | | | | | — | | | | | | 227,532 | | |
Linda S. Palczuk(7)
|
| | | | 72,100 | | | | | | 157,932 | | | | | | — | | | | | | 230,032 | | |
Peter J. Thornton(8)
|
| | | | 79,600 | | | | | | 157,932 | | | | | | — | | | | | | 237,532 | | |
Name and address of beneficial owner(1)
|
| |
Amount of
Beneficial Ownership(2) |
| |
Percentage
of Class(2) |
| ||||||
> 5% Stockholders: | | | | | | | | | | | | | |
Entities Affiliated with RTW Investments, LP(3)
40 10th Avenue, Floor 7, New York, New York 10014 |
| | | | 5,741,939 | | | | | | 7.5% | | |
Entities Affiliated with Tontine Asset Associates, LLC(4)
1 Sound Shore Drive, Suite 304 Greenwich, CT 06830-7251 |
| | | | 5,190,605 | | | | | | 6.8% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Gregory J. Divis(5)
|
| | | | 1,276,600 | | | | | | 1.64% | | |
Thomas S. McHugh(6)
|
| | | | 401,500 | | | | | | * | | |
Richard J. Kim(7)
|
| | | | 209,375 | | | | | | * | | |
Geoffrey M. Glass(8)
|
| | | | 240,700 | | | | | | * | | |
Dr. Eric J. Ende(9)
|
| | | | 292,957 | | | | | | * | | |
Dr. Mark A. McCamish(10)
|
| | | | 334,333 | | | | | | * | | |
Linda S. Palczuk(11)
|
| | | | 179,900 | | | | | | * | | |
Peter J. Thornton(12)
|
| | | | 213,055 | | | | | | * | | |
Douglas Williamson(13)
|
| | | | — | | | | | | * | | |
All executive officers and directors as a group (9 persons)
|
| | | | 3,148,420 | | | | | | 4.0% | | |
Name
|
| |
Position
|
|
Gregory J. Divis | | | Chief Executive Officer | |
Richard J. Kim | | | Chief Commercial Officer | |
Thomas S. McHugh | | | Chief Financial Officer | |
Douglas Williamson | | | Former Chief Medical Officer | |
|
2022 Peer Group
|
| |||
|
Aeglea BioTherapeutics, Inc.
|
| |
CymaBay Therapeutics, Inc.
|
|
|
Albireo Pharma, Inc.
|
| |
EyePoint Pharmaceuticals
|
|
|
Aldeyra Therapeutics, Inc.
|
| |
G1 Therapeutics, Inc.
|
|
|
Ardelyx, Inc.
|
| |
Liquidia
|
|
|
Athersys, Inc.
|
| |
Marinus Pharmaceuticals, Inc
|
|
|
AVEO Pharmaceuticals, Inc.
|
| |
Oyster Point Pharma
|
|
|
BioXcel Therapeutics, Inc
|
| |
Provention Bio, Inc.
|
|
|
Chimerix, Inc.
|
| |
VBI Vaccines, Inc.
|
|
| | | |
Y-mAbs Therapeutics
|
|
Name
|
| |
2021 Base
Salary ($) |
| |
2022 Base
Salary ($) |
| |
Increase
(%) |
| |||||||||
Gregory J. Divis
|
| | | | 544,800 | | | | | | 561,144 | | | | | | 3% | | |
Richard J. Kim(1)
|
| | | | 425,000 | | | | | | 437,750 | | | | | | 3% | | |
Thomas S. McHugh
|
| | | | 396,550 | | | | | | 420,343 | | | | | | 6% | | |
Douglas Williamson(2)
|
| | | | — | | | | | | 450,000 | | | | | | — | | |
Name
|
| |
2022 Target
Bonus (% of Base Salary) |
| |
2022 Target
Bonus ($) |
| |
2022 Actual
Bonus ($)(1) |
| |||||||||
Gregory J. Divis
|
| | | | 60% | | | | | | 336,686 | | | | | | 168,343 | | |
Richard J. Kim
|
| | | | 45% | | | | | | 196,988 | | | | | | 98,494 | | |
Thomas S. McHugh
|
| | | | 45% | | | | | | 189,154 | | | | | | 94,577 | | |
Douglas Williamson(2)
|
| | | | 45% | | | | | | 202,500 | | | | | | — | | |
Name
|
| |
Stock
Options |
| |||
Gregory J. Divis
|
| | | | 350,000 | | |
Richard J. Kim
|
| | | | 175,000 | | |
Thomas S. McHugh
|
| | | | 175,000 | | |
Name and Principal
Position |
| |
Year
|
| |
Base Salary
($)(1) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(3) |
| |
Non-Equity
Incentive Plan Compensation ($)(4) |
| |
All Other
Compensation ($)(5) |
| |
Total
Compensation ($) |
| |||||||||||||||||||||
Gregory J. Divis
Chief Executive Officer |
| | | | 2022 | | | | | $ | 561,144 | | | | | $ | — | | | | | $ | — | | | | | $ | 168,343 | | | | | $ | 24,200 | | | | | $ | 753,687 | | |
| | | 2021 | | | | | $ | 544,800 | | | | | $ | — | | | | | $ | 1,668,854 | | | | | $ | 294,192 | | | | | $ | 23,600 | | | | | $ | 2,531,446 | | | ||
| | | 2020 | | | | | $ | 520,000 | | | | | $ | — | | | | | $ | 2,246,694 | | | | | $ | 353,600 | | | | | $ | 23,400 | | | | | $ | 3,143,694 | | | ||
Richard J. Kim
Chief Commercial Officer |
| | | | 2022 | | | | | $ | 437,750 | | | | | $ | — | | | | | $ | — | | | | | $ | 98,494 | | | | | $ | 12,200 | | | | | $ | 548,444 | | |
| | | 2021 | | | | | $ | 373,510 | | | | | $ | — | | | | | $ | 2,836,088 | | | | | $ | 157,781 | | | | | $ | 11,600 | | | | | $ | 3,378,979 | | | ||
Thomas S. McHugh
Chief Financial Officer |
| | | | 2022 | | | | | $ | 420,343 | | | | | $ | — | | | | | $ | — | | | | | $ | 94,577 | | | | | $ | 11,079 | | | | | $ | 525,999 | | |
| | | 2021 | | | | | $ | 396,550 | | | | | $ | — | | | | | $ | 807,510 | | | | | $ | 142,758 | | | | | $ | 10,697 | | | | | $ | 1,357,515 | | | ||
| | | 2020 | | | | | $ | 385,000 | | | | | $ | — | | | | | $ | 898,678 | | | | | $ | 184,800 | | | | | $ | 11,400 | | | | | $ | 1,479,878 | | | ||
Douglas Williamson
Former Chief Medical Officer |
| | | | 2022 | | | | | $ | 228,461 | | | | | $ | — | | | | | $ | — | | | | | $ | 1,200,255 | | | | | $ | 465,143 | | | | | $ | 1,893,859 | | |
Name
|
| |
Grant Date
|
| |
Estimated Future
Payouts Under Non-Equity Incentive Plan Awards(1) |
| |
Estimated Future
Payouts Under Equity Incentive Plan Awards |
| |
All Other Option
Awards: Number Of Securities Underlying Options (#) |
| |
Exercise
Base Price of Option Awards ($)(3) |
| |
Grant
Date Fair Value of Stock and Option Awards ($)(2) |
| ||||||||||||||||||
|
Target
($) |
| |
Target
(#) |
| ||||||||||||||||||||||||||||||||
Gregory J. Divis
|
| | | | | | | | | | 336,686 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 8/4/2022 | | | | | | | | | | | | 350,000 | | | | | | | | | | | | 4.69 | | | | | | —(3) | | | ||
Richard J. Kim
|
| | | | | | | | | | 196,988 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 8/4/2022 | | | | | | | | | | | | 175,000 | | | | | | | | | | | | 4.69 | | | | | | —(3) | | | ||
Thomas S. McHugh
|
| | | | | | | | | | 189,154 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 8/4/2022 | | | | | | | | | | | | 175,000 | | | | | | | | | | | | 4.69 | | | | | | —(3) | | | ||
Douglas Williamson
|
| | | | | | | | | | 202,500 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2/14/2022 | | | | | | | | | | | | | | | | | | 275,000 | | | | | | 6.60 | | | | | | 1,200,255 | | |
| | | | | | | | | | | | | | | | | | | | |
Option Awards
|
| | | | | | | |||||||||
Name(1)
|
| |
Grant Date
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable(2) |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable(2) |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||||||||
Gregory J. Divis
|
| | | | 12/14/2016 | | | | | | 150,000 | | | | | | — | | | | | | | | | | | | 10.40 | | | | | | 12/14/2026 | | |
| | | 12/12/2017 | | | | | | 100,000 | | | | | | — | | | | | | | | | | | | 8.95 | | | | | | 12/12/2027 | | | ||
| | | 3/22/2018 | | | | | | 50,000 | | | | | | — | | | | | | | | | | | | 7.06 | | | | | | 3/22/2028 | | | ||
| | | 3/7/2019 | | | | | | 75,000 | | | | | | 25,000(3) | | | | | | | | | | | | 1.85 | | | | | | 3/7/2029 | | | ||
| | | 5/30/2019 | | | | | | 300,000 | | | | | | 100,000(4) | | | | | | | | | | | | 1.71 | | | | | | 5/30/2029 | | | ||
| | | 12/8/2020 | | | | | | 250,000 | | | | | | 250,000(5) | | | | | | | | | | | | 6.79 | | | | | | 12/8/2030 | | | ||
| | | 12/7/2021 | | | | | | 77,500 | | | | | | 232,500(6) | | | | | | | | | | | | 8.20 | | | | | | 12/7/2031 | | | ||
| | | 8/4/2022 | | | | | | — | | | | | | — | | | | | | 350,000(7) | | | | | | 4.69 | | | | | | 8/4/2032 | | |
| | | | | | | | | | | | | | | | | | | | |
Option Awards
|
| | | | | | | |||||||||
Name(1)
|
| |
Grant Date
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable(2) |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable(2) |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||||||||
Richard J. Kim
|
| | | | 2/15/2021 | | | | | | 87,500 | | | | | | 262,500(8) | | | | | | — | | | | | | 8.99 | | | | | | 2/15/2031 | | |
| | | 12/7/2021 | | | | | | 34,375 | | | | | | 103,125(10) | | | | | | — | | | | | | 8.20 | | | | | | 12/7/2031 | | | ||
| | | 8/4/2022 | | | | | | — | | | | | | — | | | | | | 175,000(7) | | | | | | 4.69 | | | | | | 8/4/2032 | | | ||
Thomas S. McHugh
|
| | | | 10/22/2019 | | | | | | 187,500 | | | | | | 62,500(9) | | | | | | | | | | | | 3.45 | | | | | | 10/22/2029 | | |
| | | 12/8/2020 | | | | | | 100,000 | | | | | | 100,000(11) | | | | | | | | | | | | 6.79 | | | | | | 12/8/2030 | | | ||
| | | 12/7/2021 | | | | | | 37,500 | | | | | | 112,500(12) | | | | | | | | | | | | 8.20 | | | | | | 12/7/2031 | | | ||
| | | 8/4/2022 | | | | | | — | | | | | | — | | | | | | 175,000(7) | | | | | | 4.69 | | | | | | 8/4/2032 | | |
| | |
Option Awards
|
| |
Share Awards
|
| ||||||||||||||||||
Name
|
| |
Number of
shares acquired on exercise (#) |
| |
Value
realized on exercise ($) |
| |
Number of
shares acquired on vesting (#) |
| |
Value
realized on vesting ($) |
| ||||||||||||
Gregory J. Divis
|
| | | | — | | | | | | — | | | | | | 6,000 | | | | | | 44,940 | | |
Richard J. Kim
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Thomas S. McHugh
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Douglas Williamson
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name
|
| |
Cash
Payment ($)(1) |
| |
Value of
Benefits ($)(2) |
| ||||||
Gregory J. Divis
|
| | | | 841,716 | | | | | | 39,898 | | |
Richard J. Kim
|
| | | | 437,750 | | | | | | 26,598 | | |
Thomas S. McHugh
|
| | | | 420,343 | | | | | | 26,598 | | |
Douglas Williamson
|
| | | | 450,000(3) | | | | | | 8,115(3) | | |
Name
|
| |
Cash
Payment ($)(1) |
| |
Value of
Benefits ($)(2) |
| |
Acceleration
of Equity Awards ($)(3) |
| |||||||||
Gregory J. Divis
|
| | | | 1,178,402 | | | | | | 39,898 | | | | | | 1,634,750 | | |
Richard J. Kim
|
| | | | 437,750 | | | | | | 26,598 | | | | | | 432,250 | | |
Thomas S. McHugh
|
| | | | 420,343 | | | | | | 26,598 | | | | | | 701,125 | | |
Douglas Williamson
|
| | | | N/A | | | | | | N/A | | | | | | N/A | | |
Plan category
|
| |
Number of securities
to be issued upon exercise of outstanding options and rights(1) |
| |
Weighted-average
exercise price of outstanding options and rights(2) |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Equity compensation plans approved by security
holders |
| | | | 9,360,681 | | | | | | 6.67 | | | | | | 1,532,703 | | |
Equity compensation plans not approved by security holders
|
| | | | — | | | | | | — | | | | | | 1,277,500(3) | | |
Total
|
| | | | 9,360,681 | | | | | | 6.67 | | | | | | 2,810,203 | | |
Year
|
| |
Summary
Compensation Table Total for PEO(1) |
| |
Compensation
Actually Paid to PEO(3) |
| |
Average
Summary Compensation Table Total for Non-PEO Named Executive Officers(2) |
| |
Average
Compensation Actually Paid to Non-PEO Named Executive Officers(3) |
| |
Value of Initial Fixed $100
Investment Based On: |
| | | | | | | |||||||||||||||||||||
|
Total Avadel
Shareholder Return(4) |
| |
Peer Group
Total Shareholder Return |
| |
Net Income
|
| |||||||||||||||||||||||||||||||||||
FY22
|
| | | $ | 753,687 | | | | | $ | 683,408 | | | | | $ | 989,434 | | | | | $ | 679,356 | | | | | $ | 98.90 | | | | | $ | 111.66 | | | | | $ | (137,464,000) | | |
FY21
|
| | | $ | 2,531,446 | | | | | $ | 3,483,027 | | | | | $ | 2,368,247 | | | | | $ | 2,385,129 | | | | | $ | 110.77 | | | | | $ | 126.42 | | | | | $ | (77,329,000) | | |
FY20
|
| | | $ | 3,143,694 | | | | | $ | 2,811,853 | | | | | $ | 1,479,878 | | | | | $ | 934,617 | | | | | $ | 92.40 | | | | | $ | 126.98 | | | | | $ | 7,028,000 | | |
| | |
2022
|
| |
2021
|
| |
2020
|
| |||||||||||||||||||||||||||
| | |
PEO
|
| |
Average
Non-PEO NEOs |
| |
PEO
|
| |
Average
Non-PEO NEOs |
| |
PEO
|
| |
Average
Non-PEO NEOs |
| ||||||||||||||||||
Total Compensation from Summary Compensation Table
|
| | | $ | 753,687 | | | | | $ | 989,434 | | | | | $ | 2,531,446 | | | | | $ | 2,368,247 | | | | | $ | 3,143,694 | | | | | $ | 1,479,878 | | |
Adjustments for Equity Awards | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
- Grant date fair value of option awards granted in fiscal year
|
| | | | — | | | | | $ | 400,085 | | | | | $ | 1,668,854 | | | | | $ | 1,821,799 | | | | | $ | 2,246,694 | | | | | $ | 898,678 | | |
+ Fair value of fiscal year-end of outstanding and unvested stock awards and options awards granted in fiscal year
|
| | | | — | | | | | | — | | | | | $ | 1,629,988 | | | | | $ | 1,629,367 | | | | | $ | 2,206,504 | | | | | $ | 454,439 | | |
+ Change in fair value of outstanding and unvested stock
awards and option awards granted in prior fiscal years |
| | | $ | 127,702 | | | | | $ | 86,112 | | | | | $ | 703,940 | | | | | $ | 147,481 | | | | | $ | (363,792) | | | | | $ | (53,565) | | |
+ Fair value at vesting of stock awards and options awards
granted in fiscal year that vested during fiscal year |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | |
2022
|
| |
2021
|
| |
2020
|
| |||||||||||||||||||||||||||
| | |
PEO
|
| |
Average
Non-PEO NEOs |
| |
PEO
|
| |
Average
Non-PEO NEOs |
| |
PEO
|
| |
Average
Non-PEO NEOs |
| ||||||||||||||||||
+ Change in fair value as of vesting date of stock awards
and option awards granted in prior fiscal year for which applicable vesting conditions were satisfied during fiscal year |
| | | $ | (197,981) | | | | | $ | 3,895 | | | | | $ | 286,507 | | | | | $ | 61,834 | | | | | $ | 72,141 | | | | | $ | (47,457) | | |
- Fiscal value as of prior fiscal year-end of stock awards
and option awards granted in prior fiscal years that failed to meet applicable vesting conditions during fiscal year |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total Adjustments for Equity Awards
|
| | | $ | (70,279) | | | | | $ | (310,078) | | | | | $ | 951,581 | | | | | $ | 16,883 | | | | | $ | (331,841) | | | | | $ | (545,261) | | |
Compensation Actually Paid
|
| | | $ | 683,408 | | | | | $ | 679,356 | | | | | $ | 3,483,027 | | | | | $ | 2,385,129 | | | | | $ | 2,811,853 | | | | | $ | 934,617 | | |
Name
|
| |
Series B
Preferred Shares Purchased |
| |
Total
Purchase Price |
| ||||||
RTW Master Fund. Ltd.*
|
| | | | 2,746,902 | | | | | $ | 23,348,667 | | |
RTW Innovation Master Fund, Ltd.*
|
| | | | 1,844,098 | | | | | $ | 15,674,833 | | |
RTW Venture Fund Limited*
|
| | | | 114,882 | | | | | $ | 976,497 | | |
| | |
Fiscal Year Ended
December 31, |
| |||||||||
| | |
2022
|
| |
2021
|
| ||||||
Audit Fees
|
| | | $ | 1,055,165 | | | | | $ | 958,269 | | |
Audit-related Fees
|
| | | | — | | | | | | 7,000 | | |
Tax Fees
|
| | | | — | | | | | | — | | |
All Other Fees
|
| | | | — | | | | | | — | | |
Total Fees
|
| | | $ | 1,055,165 | | | | | $ | 965,269 | | |
| | |
As of April 7, 2023:
|
| |||
1) Total number of securities subject to outstanding options and rights
|
| | | | 9,637,627 | | |
2) Weighted-average exercise price per share of outstanding options and rights(1)
|
| | | $ | 6.71 | | |
3) Weighted-average remaining term of outstanding options and rights (in years)
|
| | | | 7.60 | | |
4) Total number of shares of securities subject to outstanding full value awards(2)
|
| | | | 56,354 | | |
5) Total number of securities available for grant under all plans(3)
|
| | | | 1,696,066 | | |
Name and Position
|
| |
Share Awards
|
| |||
|
Number of
Awards (#) |
| |||||
Gregory J. Divis, Chief Executive Officer
|
| | | | 810,000 | | |
Richard Kim, Chief Commercial Officer
|
| | | | 662,500 | | |
Thomas S. McHugh, Chief Financial Officer
|
| | | | 525,000 | | |
All current executive officers, as a group
|
| | | | 1,997,500 | | |
All current directors who are not executive officers, as a group
|
| | | | 210,000 | | |
Each nominee for election as a director
|
| | | | — | | |
Each associate of any executive officers, current directors or director nominees
|
| | | | — | | |
Each other person who received or is to receive 5 percent of awards
|
| | | | — | | |
All current employees who are not executive officers, as a group
|
| | | | — | | |